文献速递垂体与肾上腺疾病

肢端肥大症的诊断

Acromegaly diagnosis.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述肢端肥大症的诊断策略。临床表现反映GH和IGF-I过量,诊断延迟常达6至10年。血清IGF-I是首选初筛试验,口服葡萄糖耐量试验中GH抑制为确诊金标准,推荐切点降至约0.4 µg/L。

要点

  • 血清IGF-I是首选初筛试验,反映整合的GH分泌
  • OGTT中GH抑制为确诊金标准,推荐切点约0.4 µg/L
  • 对生化与临床不一致者,建议重复IGF-I并测OGTT中GH

核心结论

  • 肢端肥大症诊断延迟常达6至10年,需改进筛查策略以早期识别。
  • 血清IGF-I是首选初筛试验,OGTT中GH抑制为确诊金标准。

主要发现

  • 临床表现反映慢性GH和IGF-I过量的全身效应,诊断延迟常为6至10年。
  • 许多患者初期表现为非特异性症状,包括睡眠呼吸暂停、腕管综合征、关节痛和代谢紊乱。
  • 随机GH水平常升高并与生长激素腺瘤大小相关,但OGTT中GH抑制是确诊金标准。

关键数值与推荐

  • 血清IGF-I是首选初筛试验,因其稳定且反映整合的GH分泌。
  • 解读IGF-I需考虑年龄、性别、检测变异及糖尿病、肝肾疾病、肥胖、妊娠和雌激素暴露等混杂情况。
  • 对生化与临床不一致者,建议重复IGF-I并测OGTT中GH。
  • 超敏感GH检测将推荐GH谷值切点降至约0.4 µg/L,需考虑检测特异性。

临床怎么用

  • 对无明确肢端改变但存在睡眠呼吸暂停、腕管综合征、关节痛或代谢紊乱者,应考虑筛查。
  • 初筛首选血清IGF-I,结果不一致时重复IGF-I并行OGTT测GH。
  • 解读IGF-I和GH结果时需结合年龄、性别、检测变异及合并症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical presentation of acromegaly reflects systemic effects of chronic growth hormone (GH) and insulin-like growth factor 1 (IGF-I) excess. Diagnostic delay frequently ranges from 6 to 10 years. While classical manifestations such as acral enlargement and facial coarsening are diagnostically important, many patients initially develop nonspecific symptoms, including sleep apnea, carpal tunnel syndrome, arthralgia, and metabolic disturbances. The lack of symptom/comorbidity specificity highlights the need for improved screening strategies, particularly for patients without overt acral changes. Comorbidity cluster analyses, potentially supported by artificial intelligence, may facilitate earlier identification, prompting biochemical confirmation of the diagnosis. Biochemical evaluation has benefited from advances in hormone assay harmonization and the establishment of robust age-adjusted reference ranges. Serum IGF-I is the preferred initial screening test due to its stability and reflection of integrated GH secretion. However, interpretation of assay values should consider age, sex, assay variability, and confounding conditions such as diabetes, liver or renal disease, obesity, pregnancy, and estrogen exposure. For discordant biochemical and clinical findings, it is recommended to repeat IGF-I and to measure GH during an oral glucose tolerance test (OGTT). Although random GH levels are often elevated and correlate with somatotroph adenoma size, GH suppression during OGTT is the gold-standard confirmatory test, especially in patients with borderline results. The use of ultrasensitive GH assays has lowered the recommended nadir GH cut-off threshold to ∼0.4 µg/L, with assay-specific considerations. Advances in high-resolution MRI and PET/MRI, alongside AI-driven facial recognition, electronic medical record analysis, and radiomics, offer promising avenues for earlier and more accurate diagnosis of acromegaly.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yogi-Morren D, Chanson P. Acromegaly diagnosis. J Clin Endocrinol Metab. 2026. PMID: 42056759. doi:10.1210/clinem/dgag189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。